Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KSQ Therapeutics

www.ksqtx.com

Latest From KSQ Therapeutics

David Or Goliath: Where Is Innovation Winning Through?

With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies. 

Leadership Regenerative Medicine

Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August and September.

Deals Financing

Finance Watch: Government Grants Galore And Other New Funding Sources

While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.

Financing StartUps and SMEs

CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?

CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.

Clinical Trials Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • KSQ Therapeutics
  • Senior Management
  • David Meeker, MD, CEO
    Douglas Pagán, CFO
    Frank Stegmeier, PhD, CSO
    John Trzupek, PhD, CBO
    Beni B Wolf, MD, PhD, CMO
  • Contact Info
  • KSQ Therapeutics
    Phone: (617) 674-9150
    610 Main St. North
    4th Fl.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register